Sars-Cov-2 Infection and Severity in Patients With Hematologic Malignancies: A Systematic Review Publisher Pubmed



Seyedalinaghi S¹ ; Karimi A² ; Mirzapour P¹ ; Salmani R³ ; Razi A² ; Mojdeganlou H⁴ ; Mojdeganlou P⁵ ; Qodrati M¹ ; Jashaninejad R⁶ ; Paranjkhoo P⁷ ; Dadras O⁸ ; Zarezadeh B¹ ; Afsahi AM⁹ ; Afzalian A² Show All Authors
Source: Infectious Disorders - Drug Targets Published:2023

Abstract

Introduction: Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers. Methods: We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Re-views and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results. Results: Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations. Conclusion: It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies. © 2023 Bentham Science Publishers.